1stOncology™: Cancer Intelligence Service – Page 9988 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

ForDoz Enters Contract Manufacturing Agreement for Oncology Liposomal Product with LipoMedix

On February 19, 2021 ForDoz Pharma reported that it has entered into an agreement with LipoMedix for manufacturing its lead compound, pegylated liposomal Promitil (PL-MLP) for a Phase 2 clinical study (Press release, ForDoz Pharma, FEB 19, 2021, View Source [SID1234575338]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Promitil’s unique liposomal formulation is designed for selective delivery of the therapeutic agent to cancer-affected tissues and is ideally suited for cancer chemoradiotherapy. In studies, it has been shown to be active against a broad variety of cancer types in animal models, including colorectal, gastric, pancreatic and multi-drug resistant tumors.

"Our mission is to ultimately aid in the delivery of innovative medicines that will help people live longer and better lives," said James He, founder and CEO of ForDoz. "We are proud to partner with LipoMedix to help them develop and manufacture Promitil here in the United States."

"We continue to move full-steam ahead, knowing that the patients we can help with Promitil have been long awaiting a low-toxicity and effective treatment option," said Dr. Alberto Gabizon, President and Chief Scientific Officer of LipoMedix. "We are thinking long term when selecting our partnerships and look forward to partnering with ForDoz on the next phase of our journey to bring Promitil to those who need it most."

Sanjeev Luther, Executive Chairman of the Board of LipoMedix, said, "ForDoz has a proven track record in manufacturing and in successful commercialization. Selecting the right partner for each step of the journey is critical to the strategic process of developing a drug. By leveraging ForDoz’s drug delivery technology and experience, LipoMedix will be able to effectively troubleshoot the many challenges of product development and manufacturing."

AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock

On February 19, 2021 AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") reported the closing of its previously announced underwritten public offering of 46,875,000 shares of its common stock at a price to the public of $1.60 per share (Press release, AIkido Pharma, FEB 19, 2021, View Source [SID1234575337]). As previously announced, the Company has granted to the underwriter a 30-day option to purchase up to 7,031,250 additional shares of common stock at the public offering price, less underwriting discounts and commissions.

H.C. Wainwright & Co. acted as the sole book-running manager for the offering.

The gross proceeds to the Company from the offering are $75 million, before deducting underwriting discounts and commissions and other offering expenses. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

The offering was conducted pursuant to the registration statement on Form S-3 (File No. 333-238172), as amended, previously filed with and subsequently declared effective by the Securities and Exchange Commission ("SEC") on June 18, 2020. The offering was made only by means of a prospectus supplement and accompanying base prospectus. A final prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC and are available for free on the SEC’s website located at View Source and may also be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (646) 975-6996, or by email to [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying base prospectus forming a part of the effective registration statement.

ViewRay Announces Conference Call for Fourth Quarter and Full Year 2020 Financial Results to be Held After Market on March 4, 2021

On February 19, 2021 ViewRay, Inc. (Nasdaq: VRAY) reported details relating to the release of its fourth quarter and full year 2020 financial results (Press release, ViewRay, FEB 19, 2021, View Source [SID1234575336]).

ViewRay will hold a conference call to discuss results on Thursday, March 4, 2021 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 5976583. A live webcast of the conference call will be available on the investor relations page of ViewRay’s corporate website at View Source

After the live webcast, a replay will remain available online on the investor relations page of ViewRay’s website, under "Financial Events and Webinars", for 14 days following the call. In addition, a telephonic replay of the call will be available until March 11, 2021. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number: 5976583.

Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

On February 19, 2021 Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, reported that it has closed its previously announced sale of an aggregate of 50,830,566 shares of its common stock and accompanying warrants to purchase up to an aggregate of 25,415,283 shares of its common stock, at a purchase price of $1.505 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules (Press release, Citius Pharmaceuticals, FEB 19, 2021, View Source [SID1234575335]).

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The warrants have an exercise price of $1.70 per share, are immediately exercisable, and will expire five years from the issue date.

The aggregate gross proceeds to the Company from the offering are approximately $76.5 million, before deducting the placement agent fees and other offering expenses payable by the Company. Citius currently intends to use the net proceeds from the offering for general corporate purposes, including pre-clinical and clinical development of our product candidates and working capital and capital expenditures.

The securities described above were offered pursuant to a "shelf" registration statement (File No. 333-248748) filed with the Securities and Exchange Commission (SEC) and declared effective on September 25, 2020, and an additional registration statement on Form S-3 (File No. 333-253179) filed on February 16, 2021 pursuant to Rule 462(b), which became effective automatically upon filing. The offering was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the securities that were offered has been filed with the SEC and is available at the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the securities in the offering may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by calling (646) 975-6996 or emailing [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021

On February 19, 2021 Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) reported that it will report its financial results for the fiscal year ended December 31, 2020 on Thursday, February 25, 2021, after the close of the U.S. financial markets (Press release, Y-mAbs Therapeutics, FEB 19, 2021, View Source [SID1234575334]). The announcement will be followed by a conference call and webcast with the investment community on Friday, February 26, 2021, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and President; Dr. Claus Moller, Chief Executive Officer; and Bo Kruse, Chief Financial Officer.